Abstract

Provided are an antigen binding protein and a use thereof, which specifically relate to a chimeric antigen receptor. Immune cells expressing the antigen binding protein can exhibit enhanced cytotoxicity. Also provided is the use of the antigen binding protein.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 14/54 - Interleukins [IL]
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/24 - Interleukins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents

Abstract

The present application relates to a modified tumor infiltrating lymphocyte and a use thereof, and specifically relates to a method for culturing a tumor infiltrating lymphocyte (TIL), which comprises causing a reduction of activity and/or expression of two or more types of protein of the TIL. The present application also relates to a method for preventing and/or treating a tumor by using tumor infiltrating lymphocytes.

IPC Classes  ?

• C12N 5/0781 - B cellsProgenitors thereof
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/078 - Cells from blood or from the immune system
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

Use of a tumor-infiltrating lymphocyte in the treatment of diseases, in particular, use of a tumor-infiltrating lymphocyte (TIL) in the preparation of a drug. The drug is used for preventing and/or treating tumors. The TIL is obtained by means of the following culture method: performing at least one stage of in-vitro amplification on a TIL derived from tumor tissue, wherein in a single stage of in-vitro amplification, the in-vitro-amplifed and/or non-in-vitro-amplifed TIL is co-cultured with feeder cells after same comes in contact with a T-cell activator and/or a T-cell growth factor for a certain period of time.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

The present application relates to a modified tumor-infiltrating lymphocyte (TIL) and a use thereof. Specifically, the present application relates to a method for cultivating TILs. The method comprises reducing the expression of a target gene of a TIL and/or weakening the activity. The present application also relates to a method for using TILs to prevent and/or treat tumors.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/09 - Tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is a method for culturing immune cells, which method comprises reducing the expression of and/or attenuating the activity of a YEATS domain protein family member of immune cells and/or a functional active fragment thereof. Also provided is an immune cell obtained by means of the method, and the use thereof in the preparation of a drug for preventing and/or treating tumors.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0781 - B cellsProgenitors thereof
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/0784 - Dendritic cellsProgenitors thereof
• C12N 5/0786 - MonocytesMacrophages
• C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are a modified tumor infiltrating lymphocyte (TIL) and a use thereof. Also provided is a method for culturing the TIL, comprising expression reducing and/or activity reducing of NF-κB pathway inhibiting molecules of the TIL. Further provided is a method for preventing and/or treating tumors by using the TIL.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61P 35/00 - Antineoplastic agents
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided are a method for culturing an immune cell and the use thereof. The method specifically comprises reducing the expression and/or activity of a protein containing a YEATS domain and/or a functionally active fragment thereof in the immune cell. Further provided is a method for preventing and/or treating tumors by using a cell.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/24 - Human cells one of the fusion partners being a B lymphocyte
• C12N 5/078 - Cells from blood or from the immune system
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

Provided are a modified tumor-infiltrating lymphocyte and a use thereof, relating to a method for culturing a tumor-infiltrating lymphocyte (TIL). The method comprises increasing the expression and/or activity of one or more target genes of the TIL, for example interleukin -12 and/or functional active fragments thereof. Also provided is a method for preventing and/or treating tumors by using a tumor-infiltrating lymphocyte.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are modified tumor-infiltrating lymphocyte and the use thereof, in particular provided is a method for culturing the tumor-infiltrating lymphocyte (TIL), which comprises increasing the expression and/or enhancing the activity of at least one cytokine of the TIL. Also provided is a method for preventing and/or treating tumors by using the tumor-infiltrating lymphocyte.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/20 - Interleukins

Abstract

The present application relates to a preparation method for tumor-infiltrating lymphocytes (TILs) and a use thereof, in particular, to a method for culturing TILs, comprising: subjecting TILs derived from tumor tissue and not expanded in vitro to at least one stage of in vitro expansion, wherein in the at least one stage of in vitro expansion, the TILs are made to contact one or more T cell activators and one or more immune checkpoint inhibitors. A method for preventing and/or treating a tumor by using the TILs is further provided.

IPC Classes  ?

• C12N 5/0781 - B cellsProgenitors thereof
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/078 - Cells from blood or from the immune system
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are a preparation method for a tumor infiltrating lymphocyte, and a use thereof, particularly relating to a method for culturing a tumor infiltrating lymphocyte, comprising: subjecting a TIL, which is derived from tumor tissues and not amplified in vitro, to in vitro amplification of at least one stage, wherein the TIL is brought into contact with a CD28 agonist in the in vitro amplification of at least one stage. Further provided is a method for preventing and/or treating tumors by means of using the tumor infiltrating lymphocyte.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 5/09 - Tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

A method for culturing tumor infiltrating lymphocytes (TIL), the method comprising co-culturing the amplified TIL with feeder cells after contacting the TIL with a T cell co-stimulatory molecule and/or a T cell growth factor for a period of time. In addition, further provided is a method for preventing and/or treating tumors by means of using the tumor infiltrating lymphocytes of the present application.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Provided is an antigen-binding protein capable of binding to PD-1. Also provided are a preparation method for and an application of the antigen-binding protein.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/13 - Immunoglobulins
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents